Richard S. Geary's Insider Trades & SAST Disclosures
Richard S. Geary's most recent trade in Ionis Pharmaceuticals Inc was a trade of 415 Common Stock done at an average price of $28.2 . Disclosure was reported to the exchange on Feb. 28, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Richard S. Geary.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Other type of transaction at price $ 28.21 per share. | 28 Feb 2025 | 415 | 99,492 (0%) | 0% | 28.2 | 11,708 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 3,820 | 100,483 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 32.40 per share. | 30 Jan 2025 | 1,406 | 99,077 (0%) | 0% | 32.4 | 45,561 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 33,000 | 79,625 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 22,000 | 64,801 | - | - | Performance Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 18,901 | 60,724 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 18,901 | 103,735 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 32.86 per share. | 15 Jan 2025 | 7,072 | 96,663 (0%) | 0% | 32.9 | 232,407 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 22,000 | 22,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Other type of transaction at price $ 38.64 per share. | 30 Aug 2024 | 11 | 84,834 (0%) | 0% | 38.6 | 425 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 49.63 per share. | 28 Aug 2024 | 331 | 84,823 (0%) | 0% | 49.6 | 16,428 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 49.16 per share. | 28 Aug 2024 | 320 | 85,154 (0%) | 0% | 49.2 | 15,731 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 48.00 per share. | 05 Aug 2024 | 2,430 | 85,508 (0%) | 0% | 48 | 116,640 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | Officer Level 14 | Other type of transaction at price $ 34.43 per share. | 29 Feb 2024 | 604 | 87,938 (0%) | 0% | 34.4 | 20,793 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 50.04 per share. | 02 Feb 2024 | 1,995 | 87,300 (0%) | 0% | 50.0 | 99,836 | Common Stock |
| Ionis Pharmaceuticals Inc | S. Geary Richard | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 3,820 | 89,295 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Richard Geary S. | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 50.04 per share. | 01 Feb 2024 | 1,961 | 87,334 (0%) | 0% | 50.0 | 98,135 | Common Stock |
| Ionis Pharmaceuticals Inc | S. Richard Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 19,852 | 92,813 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | S. Geary Richard | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 19,852 | 46,625 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Richard Geary S. | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 50.42 per share. | 16 Jan 2024 | 7,338 | 85,475 (0%) | 0% | 50.4 | 369,960 | Common Stock |
| Ionis Pharmaceuticals Inc | S. Geary Richard | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 20,400 | 66,477 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Geary S. Richard | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 17,000 | 42,801 | - | - | Performance Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | S. Richard Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 27,200 | 27,200 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Geary S. Richard | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2023 | 6,500 | 4,112 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Richard Geary S. | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.34 per share. | 20 Dec 2023 | 6,500 | 79,461 (0%) | 0% | 47.3 | 307,710 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 49.64 per share. | 20 Dec 2023 | 6,500 | 72,961 (0%) | 0% | 49.6 | 322,643 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 49.29 per share. | 20 Dec 2023 | 4,112 | 72,961 (0%) | 0% | 49.3 | 202,681 | Common Stock |
| Ionis Pharmaceuticals Inc | S. Richard Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2023 | 4,112 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Richard Geary S. | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.34 per share. | 20 Dec 2023 | 4,112 | 77,073 (0%) | 0% | 47.3 | 194,662 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 49.21 per share. | 14 Dec 2023 | 6,571 | 72,961 (0%) | 0% | 49.2 | 323,381 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard Geary S. | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.34 per share. | 14 Dec 2023 | 6,571 | 79,532 (0%) | 0% | 47.3 | 311,071 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 6,571 | 14,654 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 50.19 per share. | 14 Dec 2023 | 4,042 | 72,961 (0%) | 0% | 50.2 | 202,856 | Common Stock |
| Ionis Pharmaceuticals Inc | S. Richard Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 4,042 | 10,612 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Geary S. Richard | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.34 per share. | 14 Dec 2023 | 4,042 | 77,003 (0%) | 0% | 47.3 | 191,348 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Other type of transaction at price $ 30.51 per share. | 28 Feb 2023 | 575 | 72,960 (0%) | 0% | 30.5 | 17,546 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 3,822 | 74,305 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 40.66 per share. | 03 Feb 2023 | 1,920 | 72,385 (0%) | 0% | 40.7 | 78,070 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 21,983 | 78,356 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 21,983 | 46,077 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 39.57 per share. | 17 Jan 2023 | 7,873 | 70,483 (0%) | 0% | 39.6 | 311,525 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2023 | 17,207 | 68,060 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2023 | 14,338 | 25,801 | - | - | Performance Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 22,942 | 22,942 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Other type of transaction at price $ 28.37 per share. | 28 Feb 2022 | 621 | 56,373 (0%) | 0% | 28.4 | 17,620 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 21,391 | 50,853 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 21,391 | 63,357 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.12 per share. | 18 Jan 2022 | 7,605 | 55,752 (0%) | 0% | 30.1 | 229,063 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2022 | 15,284 | 72,244 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2022 | 11,463 | 11,463 | - | - | Performance Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 30,567 | 30,567 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Offc | Other type of transaction at price $ 33.80 per share. | 31 Aug 2021 | 46 | 41,966 (0%) | 0% | 33.8 | 1,555 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Offc | Other type of transaction at price $ 44.54 per share. | 26 Feb 2021 | 414 | 41,920 (0%) | 0% | 44.5 | 18,440 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Offc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 22,714 | 22,714 | - | - | Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Offc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 17,598 | 47,904 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Offc | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 17,598 | 34,246 | - | - | Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Offc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.28 per share. | 15 Jan 2021 | 6,398 | 41,506 (0%) | 0% | 61.3 | 392,069 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Chief Development Offc | Sale of securities on an exchange or to another person at price $ 59.50 per share. | 13 Jan 2021 | 141 | 30,306 (0%) | 0% | 59.5 | 8,390 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 51,107 | 51,107 | - | - | Employee Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2020 | 11,920 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.87 per share. | 25 Nov 2020 | 11,920 | 42,367 (0%) | 0% | 39.9 | 475,250 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Development | Sale of securities on an exchange or to another person at price $ 50.05 per share. | 25 Nov 2020 | 11,920 | 30,447 (0%) | 0% | 50.1 | 596,596 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.87 per share. | 23 Nov 2020 | 10,700 | 41,147 (0%) | 0% | 39.9 | 426,609 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Development | Sale of securities on an exchange or to another person at price $ 50.11 per share. | 23 Nov 2020 | 10,700 | 30,447 (0%) | 0% | 50.1 | 536,177 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2020 | 10,700 | 14,300 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2020 | 2,380 | 11,920 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.87 per share. | 23 Nov 2020 | 2,380 | 32,827 (0%) | 0% | 39.9 | 94,891 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Development | Sale of securities on an exchange or to another person at price $ 50.83 per share. | 23 Nov 2020 | 2,380 | 30,447 (0%) | 0% | 50.8 | 120,975 | Common Stock |
| Ionis Pharmaceuticals Inc | Richard S. Geary | EVP, Development | Other type of transaction at price $ 44.00 per share. | 31 Aug 2020 | 1 | 30,447 (0%) | 0% | 44 | 44 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges